Top Level Navigation

The deficiency of C1 inhibitor and its treatment

In this article, we review the traditional therapies of hereditary angioedema (HAE) that have been used for several years. Some of these therapies were proposed before the definition of the underlying defect and the understanding of the pathogenesis of the disease. We also describe new compounds under investigation at present as potential therapies for HAE. Two of these new therapies (a plasma-kallikrein inhibitor and a bradykinin B(2)-receptor antagonist) have been developed based on the understanding that the pathogenesis of symptoms was mainly due to kallikrein activation and bradykinin release. [References: 72].

212(4-5):325-331

Available online at: http://www.sciencedirect.com/science/article/pii/S0171298507000496 (small fee)

Comments are closed.